Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

Melanoma is a disease characterized by lesions that activate ERK. Though 70% of cutaneous melanomas harbor activating mutations in the BRAF and NRAS genes, the alterations that drive tumor progression in the remaining 30% are largely undefined. Vemurafenib, a selective inhibitor of RAF kinases, has...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Nissan, Moriah H., Pratilas, Christine A., Jones, Alexis M., Ramirez, Ricardo, Won, Helen, Liu, Cailian, Tiwari, Shakuntala, Kong, Li, Hanrahan, Aphrothiti J., Yao, Zhan, Merghoub, Taha, Ribas, Antoni, Chapman, Paul B., Yaeger, Rona, Taylor, Barry S., Schultz, Nikolaus, Berger, Michael F., Rosen, Neal, Solit, David B.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4005042/
https://ncbi.nlm.nih.gov/pubmed/24576830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2625
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky